Zai Lab
Building 65, 1000 Zhangheng Road
Zhangjiang Hi-tech Park
Pudong
Shanghai
201203
China
Tel: 86-21-6163-2588
Fax: 86-21-6163-2570
Website: http://www.zailaboratory.com/
50 articles about Zai Lab
-
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
4/15/2024
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the first quarter of 2024 and recent corporate updates, after the closing of the U.S. equity markets on Wednesday, May 8, 2024.
-
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
4/11/2024
The Executive Officers of Zai Lab Limited, Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards.
-
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or...
4/1/2024
Zai Lab Limited partner Bristol Myers Squibb announced the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints.
-
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
3/27/2024
Zai Lab Limited partner Novocure announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer following stereotactic radiosurgery.
-
Zai Lab Announces Participation in March Investor Conference
3/6/2024
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in March 2024.
-
Zai Lab Announces Participation in January Investor Conference
12/19/2023
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024.
-
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
11/8/2022
Zai Lab Limited today announced the appointment of Dr. Peter Huang as its Chief Scientific Officer (CSO), effective immediately.
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
9/27/2022
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK ® (tisotumab vedotin-tftv).
-
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
6/3/2022
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer.
-
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
-
The SEC added 12 China companies to their delisting watchlist this week. The companies will need to release evidence by May 3 to remain listed.
-
When ImmunoGen announced top-line results from the Phase III SORAYA trial in November 2021, the primary endpoint - confirmed objective response rate - was met at 32.4%.
-
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
-
BioSpace Global Roundup, Jan. 2
1/2/2020
Companies from across the globe announce updates to their business and pipeline. -
It was another busy week for clinical trials. Here’s a look.
-
Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China
7/2/2019
Collaboration will expand potential to bring new medicines to patients with cancer around the world
-
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
6/11/2019
Deciphera Intends to Expand Ripretinib Development Program in Gastrointestinal Stromal Tumors (GIST) by Potentially Adding China Sites to the Ongoing Global Phase 3 INTRIGUE Study
-
Ablexis Announces Multi-Target Licensing Agreement with Zai Lab (US)
6/3/2019
Ablexis grants rights to use the AlivaMab™ Mouse platform for research, development and potential commercialization of antibodies
-
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
11/14/2018
Novocure announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China
-
Novocure and Zai Lab to Host Investor Event on November 14, 2018
11/7/2018
Novocure announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating Fields in Greater China and address questions from the audience.